HCWB Insider Trading

Insider Ownership Percentage: 49.90%
Insider Buying (Last 12 Months): $255,927.10
Insider Selling (Last 12 Months): $0.00

HCW Biologics Insider Trading History Chart

This chart shows the insider buying and selling history at HCW Biologics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

HCW Biologics Share Price & Price History

Current Price: $1.12
Price Change: Price Increase of +0.01 (0.90%)
As of 05/23/2024 01:00 AM ET

This chart shows the closing price history over time for HCWB up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365

HCW Biologics Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
9/14/2023Hing C WongCEOBuy1,800$2.08$3,744.0015,314,868View SEC Filing Icon  
9/13/2023Gary M WinerDirectorBuy546$2.05$1,119.3015,959View SEC Filing Icon  
9/13/2023Rebecca ByamCFOBuy5,000$2.10$10,500.00573,946View SEC Filing Icon  
9/11/2023Gary M WinerDirectorBuy99$2.05$202.9514,913View SEC Filing Icon  
9/11/2023Rebecca ByamCFOBuy5,000$2.05$10,250.00563,946View SEC Filing Icon  
9/8/2023Rebecca ByamCFOBuy5,000$2.02$10,100.00558,946View SEC Filing Icon  
9/7/2023Gary M WinerDirectorBuy63$1.95$122.8514,813View SEC Filing Icon  
9/6/2023Rebecca ByamCFOBuy5,000$1.95$9,750.00548,946View SEC Filing Icon  
9/5/2023Gary M WinerDirectorBuy400$1.75$700.0014,750View SEC Filing Icon  
6/9/2023Rebecca ByamCFOBuy20,000$2.06$41,200.00543,946View SEC Filing Icon  
6/8/2023Lee FlowersSVPBuy10,000$2.16$21,600.00111,308View SEC Filing Icon  
6/7/2023Rebecca ByamCFOBuy20,000$2.03$40,600.00519,250View SEC Filing Icon  
6/5/2023Rebecca ByamCFOBuy20,000$1.67$33,400.00480,188View SEC Filing Icon  
6/1/2023Hing C WongCEOBuy800$1.62$1,296.0015,312,268View SEC Filing Icon  
5/30/2023Gary M WinerDirectorBuy850$1.52$1,292.0013,850View SEC Filing Icon  
5/30/2023Hing C WongCEOBuy3,000$1.55$4,650.0015,309,468View SEC Filing Icon  
5/26/2023Rebecca ByamCFOBuy20,000$1.66$33,200.00460,188View SEC Filing Icon  
5/24/2023Rebecca ByamCFOBuy20,000$1.61$32,200.00420,188View SEC Filing Icon  
5/22/2023Rebecca ByamCFOBuy33,450$1.53$51,178.50395,152View SEC Filing Icon  
9/14/2022Rebecca ByamCFOBuy15,000$2.58$38,700.00327,952View SEC Filing Icon  
9/12/2022Rebecca ByamCFOBuy15,000$2.65$39,750.00297,952View SEC Filing Icon  
9/8/2022Hing C WongCEOBuy4,000$2.67$10,680.0015,300,468View SEC Filing Icon  
8/29/2022Rebecca ByamCFOBuy10,000$2.57$25,700.00265,752View SEC Filing Icon  
8/26/2022Rebecca ByamCFOBuy10,000$2.54$25,400.00255,752View SEC Filing Icon  
8/24/2022Rebecca ByamCFOBuy50,000$2.50$125,000.00205,452View SEC Filing Icon  
6/13/2022Rebecca ByamCFOBuy7,596$2.08$15,799.6896,596View SEC Filing Icon  
6/10/2022Gary M WinerDirectorBuy1,500$2.13$3,195.0013,000View SEC Filing Icon  
6/9/2022Hing C WongCEOBuy2,000$2.25$4,500.0015,284,948View SEC Filing Icon  
6/8/2022Gary M WinerDirectorBuy1,000$2.27$2,270.0010,500View SEC Filing Icon  
6/6/2022Gary M WinerDirectorBuy1,000$2.13$2,130.008,500View SEC Filing Icon  
6/2/2022Rick S GreeneDirectorBuy4,800$2.09$10,032.008,411View SEC Filing Icon  
12/6/2021Jin-An JiaoVPBuy10,000$2.42$24,200.00View SEC Filing Icon  
See Full Table

SEC Filings (Institutional Ownership Changes) for HCW Biologics (NASDAQ:HCWB)

2.96% of HCW Biologics stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

HCW Biologics Institutional Trading History

Reporting DateHedge FundShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails
5/2/2024Pullen Investment Management LLC85,116$0.15M0.1%N/A0.225%Search for SEC Filing on Google Icon
2/9/2024Avantax Planning Partners Inc.179,541$0.22M0.0%N/A0.499%Search for SEC Filing on Google Icon
2/9/2023HighTower Advisors LLC269,869$0.52M0.0%+19.6%0.752%Search for SEC Filing on Google Icon
11/15/2021HighTower Advisors LLC14,000$45K0.0%N/A0.039%Search for SEC Filing on Google Icon
Data available starting January 2016

See Full Table
HCW Biologics logo
HCW Biologics Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases in the United States. The company's lead products include HCW9218, which is in Phase 1 clinical chemo-refractory/chemo-resistant solid tumors with pancreatic, ovarian, breast, prostate, and colorectal cancers, as well as Phase 2 clinical trial with metastatic advanced stage ovarian cancer patients; and HCW9302 for autoimmune and proinflammatory diseases, such as alopecia areata diseases. It also develops HCW9201, a cell-based therapy that is in Phase I clinical trials for the treatment of patients with relapsed/refractory acute myelogenous leukemia; and HCW9206, an injectable immunotherapeutic to use as adjuvant for adoptive cell therapy in cancer treatment. HCW Biologics Inc. was incorporated in 2018 and is headquartered in Miramar, Florida.
Read More on HCW Biologics

Today's Range

Now: $1.12
Low: $1.10
High: $1.12

50 Day Range

MA: $1.48
Low: $1.10
High: $1.77

52 Week Range

Now: $1.12
Low: $0.91
High: $2.32


15,764 shs

Average Volume

16,361 shs

Market Capitalization

$42.36 million

P/E Ratio


Dividend Yield




Who are the company insiders with the largest holdings of HCW Biologics?

HCW Biologics' top insider investors include:
  1. Hing C Wong (CEO)
  2. Rebecca Byam (CFO)
  3. Lee Flowers (SVP)
  4. Gary M Winer (Director)
  5. Rick S Greene (Director)
Learn More about top insider investors at HCW Biologics.

Who are the major institutional investors of HCW Biologics?

HCW Biologics' top institutional investors include:
  1. Pullen Investment Management LLC — 0.23%
Learn More about top institutional investors of HCW Biologics stock.

Which institutional investors are buying HCW Biologics stock?

Within the previous quarter, HCWB stock was purchased by institutional investors including:
  1. Pullen Investment Management LLC
Within the previous year, these company insiders have bought HCW Biologics stock:
  1. Hing C Wong (CEO)
  2. Rebecca Byam (CFO)
  3. Lee Flowers (SVP)
  4. Gary M Winer (Director)
  5. Rick S Greene (Director)
Learn More investors buying HCW Biologics stock.